Mirabaud advises pharmaceutical trailblazer Scailyte on CHF 6 million series a funding
- Mirabaud acted as exclusive advisor to Scailyte in series A funding with CHF 6 million raised
- The company will use the investment to advance its endometriosis biomarker at clinical evaluation stage and the development of strategic partnerships in immuno-oncology
- The Mirabaud Advisors team managed the transaction using its expansive network of investors
Zurich, 21 September 2022 – Mirabaud Advisors has acted as exclusive advisor to Swiss pharmaceutical innovator Scailyte in a CHF 6 million Series A fund raise from various investors
Scailyte will use the investment to advance its endometriosis biomarker in the prototype validation stage in the US, its primary target market. In addition, the company will continue building strategic partnerships in transactional oncology to increase the success rate of novel cancer therapies in the clinic. Scailyte will also continue expanding the discovery capabilities of ScaiVision, its best-in-class single-cell analytics platform.
Gianpaolo Chiriano, Managing Director at Mirabaud Group, stated, ‘We are very pleased to have helped Scailyte secure this financing as a basis for the future achievement of the company’s milestones. At Mirabaud, we are committed to supporting our clients over the long term and, in doing so, we aim to support the development of breakthrough technologies. Our scope is to connect science-driven and disruptive companies with high-premium investment communities and to lead them towards success, making a social impact and creating value globally. This transaction reinforces Mirabaud’s position as a leading advisor in the financing of healthcare-related projects at the international level among institutional and private investors.’